

CONFIDENTIAL

PRICING SUPPLEMENT DATED JULY 6, 2018



*The information in this pricing supplement dated July 6, 2018 (the “Pricing Supplement”) supplements the preliminary international offering memorandum dated June 27, 2018 (the “International Offering Memorandum”) of Roche Bobois S.A., and supersedes the information in the International Offering Memorandum to the extent inconsistent with the information in the International Offering Memorandum. Unless otherwise indicated, terms used but not defined herein have the meaning assigned to such terms in the International Offering Memorandum.*

<b>Issuer:</b>	Roche Bobois S.A. (Formerly “Furn-Invest S.A.S.”)			
<b>Offering price:</b>	€ 20.00 per offered share			
<b>Number of existing ordinary shares sold (before exercise of the Overallotment Option):</b>	Global Placement:	842,563	existing	ordinary shares
	OPO:	144,958	existing	ordinary shares
	Total number of existing ordinary shares sold in the Offering:	987,521	existing	ordinary shares
<b>Nature and number of the ordinary shares for which admission has been requested:</b>	The securities of Roche Bobois S.A. for which admission to trading on Euronext Paris has been requested are all existing shares, i.e., 9,875,216 ordinary shares of Roche Bobois S.A. (the “Existing Shares”).			
<b>Overallotment Option</b>	A maximum of 148,128 additional Existing Shares.			
	In the event of full exercise of the Overallotment Option, the number of Existing Shares sold in the Offering will be 1,135,649. The Overallotment Option may be exercised by Portzamparc Groupe BNP Paribas in the name and on behalf of the Joint Lead Managers and Joint Bookrunners from July 6, 2018 to August 6, 2018 (inclusive).			
<b>Gross proceeds to the Selling Shareholders:</b>	€ 19,750,420 million (before exercise of the Overallotment Option).			

**Indicative Timetable**

**July 9, 2018**

- Beginning of trading of the Existing Shares on an as-if-when delivered basis (*sous la forme de promesses d'actions*) on Euronext Paris (until July 10, 2018 inclusive)

**July 10, 2018**

- Settlement-delivery of the OPO and the Global Placement

**July 11, 2018**

- Beginning of trading of the Company's shares on Euronext Paris under the trading line "Roche Bobois"

**August 6, 2018**

- Deadline for exercising the Overallotment Option
- End of the stabilization period, as the case may be

**Exchange:**

Roche Bobois S.A. has applied for admission to trading of all its existing ordinary shares on Euronext Paris

**Ticker symbol:**

RBO

**Managers:**

Joint Global Coordinators and Joint Bookrunners:

Portzamparc Groupe BNP Paribas

Oddo BHF SCA

The shares offered hereby have not been and will not be registered under the U.S. Securities Act of 1933 (the “**Securities Act**”), or under the securities laws of any state or other jurisdiction within the United States, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws. The shares are only being offered (a) outside the United States of America in offshore transactions in accordance with Regulation S under the Securities Act, (b) in the United States by Roche Bobois only to a limited number of “qualified institutional buyers” (or “QIBs”) as defined in Rule 144A under the Securities Act, in transactions that are exempt from or not subject to the Securities Act.

This Pricing Supplement has not been and will not be submitted to the clearance procedures of the French *Autorité des marchés financiers* (the “**AMF**”), and accordingly may not be distributed to the public in France or used in connection with any offer to purchase or sell any of the ordinary shares to the public in France. For the purpose of the Offering, a *prospectus*, which received visa no. 18-257 dated June 22, 2018 from the AMF, in the French language has been prepared (consisting of (i) a registration document (*Document de base*), which was registered by the AMF on June 4, 2018 under no. I.18-046 and (ii) a securities note (*Note d’opération*), dated June 22, 2018, and includes a section describing certain risk factors relating to Roche Bobois and the Offering, as well as a summary of the Company’s business). Such *prospectus* is the only document by which offers to acquire shares may be made to the public in France.

This Pricing Supplement and any other material in relation to the ordinary shares described herein is addressed to and intended for persons who are (i) outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”), (iii) high net worth entities and other such persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies”, “unincorporated associations”, etc.) or (iv) other persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons in (i), (ii), (iii) and (iv) together being referred to as “**Relevant Persons**”). This Pricing Supplement is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this Pricing Supplement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. The ordinary shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ordinary shares will be engaged in only with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.

No action has been taken nor will be taken to allow the Company’s shares to be offered to the public in any member state of the European Economic Area (the “**Member State**”) that has implemented the Prospectus Directive (other than in France) where a prospectus may be required to be published in such Member State, except that the shares may be offered in such Member States (i) to qualified investors, as defined in the Amending Directive, (ii) to fewer than 150 individuals or legal entities other than qualified investors (as defined in the Prospectus Directive) per Member State, or (iii) in any other circumstances falling under Article 3(2) of the Prospectus Directive. For the purposes of this paragraph, (i) the expression an “**offer of the shares to the public**” in relation to any shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to subscribe for the shares, as such expression may be varied in the Member State, (ii) the expression “**Prospectus Directive**” means the Directive 2003/71/EC of 4 November 2003, as implemented in a member state (as modified including by the Amending Directive, insofar as it has been implemented by each Member State) and (iii) the expression “**Amending Directive**” means the Directive 2010/73/UE of the European Parliament and of the Council of 24 November 2010.

The information contained in this Pricing Supplement has been furnished by us and other sources we believe reliable. This Pricing Supplement is being furnished by us solely for the purpose of enabling a prospective investor to consider the subscription or the purchase of our ordinary shares in the Global Placement described herein. No representation or warranty, express or implied, is made by the Managers as to the accuracy or completeness of the information contained in this Pricing Supplement, and nothing contained in this Pricing Supplement is, or shall be relied upon as, a promise or representation, whether as to the past or the future.

This Pricing Supplement is personal to the offeree to whom it has been delivered by the Managers and does not constitute an offer to any person or to the public in general to subscribe for or purchase or otherwise acquire the ordinary shares. Any reproduction or distribution of this Pricing Supplement, in whole or in part, and any disclosure of its contents or use of any information herein for any purpose other than considering an investment in the ordinary shares offered hereby is prohibited. By accepting delivery of this Pricing Supplement, prospective investors agree to the foregoing.